Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Market price (% of par)
-
90.57%
-
Total 13F principal
-
$505,163,049
-
Principal change
-
+$29,721,675
-
Total reported market value
-
$458,227,307
-
Number of holders
-
47
-
Value change
-
+$27,473,180
-
Number of buys
-
20
-
Number of sells
-
21
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q3 2020
As of 30 Sep 2020,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 was held by
47 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$505,163,049
in principal (par value) of the bond.
The largest 10 bondholders included
STEELHEAD PARTNERS LLC, CANYON CAPITAL ADVISORS LLC, ADVENT CAPITAL MANAGEMENT /DE/, UBS ASSET MANAGEMENT AMERICAS INC, WOLVERINE ASSET MANAGEMENT LLC, Davidson Kempner Capital Management LP, LAZARD ASSET MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP, Nuveen Asset Management, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
47
institutional bondholders reporting positions
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.